
Keywords: استیل اسلسیلیک اسید; Uric acid; Hyperuricemia; Acute coronary syndrome; Percutaneous coronary intervention; Long-term adverse outcomes; ACE-I; angiotensin-converting-enzyme inhibitor; ACS; acute coronary syndrome; ARB; angiotensin-receptor blocker; ASS; acetylsalicylic acid;